Use of Erythropoiesis-Stimulating Agents in the Treatment of Anemia in Patients With Systolic Heart Failure
Conclusion:
There is inconclusive evidence to suggest that the use of ESAs in treating anemia in patients with heart failure is beneficial. Although ESAs demonstrated a clear ability for increasing hemoglobin levels, the data regarding clinical outcomes such as exercise parameters, quality of life, and hospitalizations are conflicting. In addition, a mortality benefit has not been shown; therefore, the potential for improved symptomatology must be weighed against the potential for adverse events.
Source: Journal of Cardiovascular Pharmacology and Therapeutics - Category: Cardiology Authors: Lindquist, D. E., Cruz, J. L., Brown, J. N. Tags: Clinical Studies Source Type: research
More News: Anemia | Cardiology | Cardiovascular | Drugs & Pharmacology | Heart | Heart Failure | Hematology | Sports Medicine | Statistics | Study